Search results
Results from the WOW.Com Content Network
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology.
To say that Ginkgo Bioworks' (NYSE: DNA) stock is in a bit of a rough patch doesn't quite capture it. With the price of its shares down by 81% in 2024 alone, many investors are likely wishing they ...
It was also during this period that Knight's interests in biological systems began. Inspired in part by the work of Harold J. Morowitz, a Yale physicist and biologist, Knight studied biochemistry, genetics, and cellular biology, and set up a biology lab within the MIT AI Laboratory.
Things have gotten so bad for biotech company Ginkgo Bioworks Holdings (NYSE: DNA) that it recently had to do a 1-for-40 reverse stock split to keep its share price up and stay listed on the New ...
Sadly, Ginkgo Bioworks' businesses aren't growing these days. They're shrinking at a frightening pace. Diagnostics or "Biosecurity" sales collapsed by 71% year over year to just $10 million.
Science & Tech. Shopping. Sports
Agapakis is now the Creative Director of the Boston-based biotechnology company Ginkgo Bioworks, known as "The Organism Company," which specializes in genetically engineering organisms like yeast and bacteria for a number of applications—from engineering perfumes and food to engineering solutions for more sustainable agriculture.
In July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal. [29] On October 3, 2023, Zymergen filed for Chapter 11 bankruptcy. [30] On February 5, 2024, Zymergen announced that it would liquidate after selling all of its remaining assets and employee layoffs. [31]